With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Novel Genomic Diagnostics for Intracranial Germ Cell Tumors||Connecticut Children's Medical Center Foundation, Inc. / Ching Lau, MD/PhD||Reach Grants||2021||Connecticut|
|Dual PTK7/GD2 Gamma Delta CAR T Cell Therapy for Neuroblastoma||Emory University / Kelly Goldsmith, MD & H. Trent Spencer, PhD & Chris B. Doering, PhD||Reach Grants||2021||Georgia|
|Stapled Peptide PROTAC: A 3-in-1 Treatment for Pediatric Solid Tumors||Dana-Farber Cancer Institute / Loren Walensky, MD/PhD||Reach Grants||2021||Massachusetts|
|Optimization of Drug Efflux and Brain Clearance to Improve CED of Targeted Therapy to H3K27M DMG||Mayo Clinic / David Daniels, MD/PhD||Reach Grants||2021||Minnesota|
|A leukemia organoid platform for dissection and targeting of tumor-niche interactions||Columbia Institute for Cancer Genetics / Adolfo Ferrando, MD/PhD||Innovation Grants||2021||New York|
|IND-Enabling Studies for WNTinib, a Novel Selective Therapeutic for CTNNB1 Mutant Hepatoblastomas||Icahn School of Medicine at Mount Sinai / Ernesto Guccione, PhD & Josep Llovet, MD & Arvin Dar, PhD||Reach Grants||2021||New York|
|Phosphopeptides as shared targets for donor derived T cell therapy of AML||Memorial Sloan-Kettering Cancer Center / Richard O'Reilly, MD||Innovation Grants||2021||New York|
|Role of H3.3-G34R mutation in pediatric high-grade glioma||University of Texas M.D. Anderson Cancer Center / Jian Hu, PhD||Innovation Grants||2021||Texas|
|Choline Kinase and Alkylating Agent Resistance in Refractory Childhood Leukemias||Boston Children's Hospital / Alejandro Gutierrez, MD||Innovation Grants||2021||Massachusetts|
|Targeting CCAAT/enhancer binding proteins CEBPB and CEBPD in neuroblastoma||Columbia University / Darrell Yamashiro, MD/PhD||Innovation Grants||2021||New York|
|Unraveling metabolic dependencies in childhood supratentorial ependymomas.||Regents of the University of Michigan / Sriram Venneti, MD/PhD||Innovation Grants||2021||Michigan|
|Loss of ER-mitochondria contacts drives therapy resistance in neuroblastoma||Children's Hospital of Philadelphia / Michael Hogarty, MD||Innovation Grants||2021||Pennsylvania|
|Hematopoietic stem cell function in familial platelet disorder therapy||University of Massachusetts Medical School / Lucio Castilla, PhD||Innovation Grants||2021||Massachusetts|
|In-vivo characterization of MYCN-driven immunosuppression||University of California San Francisco / William Weiss, MD/PhD||Innovation Grants||2021||California|
|Targeting tumor associated macrophages in metastatic Ewing sarcoma (ES)||New York Medical College / Mitchell Cairo, MD||Innovation Grants||2021||New York|
|Targeting EZHIP as a therapeutic strategy for infantile ependymomas||University of Wisconsin - Madison / Peter Lewis, PhD||Innovation Grants||2021||Wisconsin|
|Novel targeting approach for pediatric B-cell malignancies||Thomas Jefferson University / Christine Eischen, PhD||Innovation Grants||2021||Pennsylvania|